Effects of recombinant bovine interleukin-8 (rbIL-8) treatment on health, metabolism, and lactation performance in Holstein cattle III: Administration of rbIL-8 induces insulin resistance in bull calves

• Published in: Journal of dairy science 2019-11, Vol.102 (11), p.10329-10339
• Main Authors: Zinicola, M., Menta, P.R., Ribeiro, B.L., Boisclair, Y., Bicalho, R.C.
• Format: Article
• Language: English
• Subjects: 3-Hydroxybutyric Acid - blood; Animals; Area Under Curve; Blood Glucose - analysis; Blood Glucose - drug effects; Blood Glucose - metabolism; Blood Urea Nitrogen; Body Temperature; Body Weight; Cattle; chemokine; Fatty Acids, Nonesterified - blood; Glucose Tolerance Test; Haptoglobins - analysis; inflammation; Insulin - blood; Insulin Resistance; insulin sensitivity; Insulin-Like Growth Factor I; Interleukin-8 - administration & dosage; Interleukin-8 - adverse effects; Interleukin-8 - pharmacology; Leukocyte Count - veterinary; Male; Recombinant Proteins - administration & dosage; Recombinant Proteins - adverse effects; Recombinant Proteins - pharmacology
• ISSN: 0022-0302; 1525-3198
• DOI: 10.3168/jds.2019-16336

Our previous work has suggested that recombinant bovine interleukin-8 (rbIL-8) treatment might influence cow metabolism. Therefore, this study was conducted to initially assess the effects of systemic administration of rbIL-8 on response to a glucose challenge, blood metabolites, insulin, growth hormone, insulin-like growth factor-1, immune cell populations, and inflammatory parameters in Holstein bull calves. Calves from 30 ± 6 d of life were individually housed and randomly allocated to 1 of 2 treatment groups: rbIL-8 (rbIL-8, n = 10) and control (CTR, n = 8). Calves assigned to the rbIL-8 group received 1 s.c. injection (d 1, 0900 h) and 6 i.v. injections (d 1 at 1600 h, d 2 and 3 at 0900 h and 1600 h, and d 4 at 0900 h) of rbIL-8 (4 μg/kg of body weight), whereas the CTR group received 2 mL of sterile saline solution at each time point. Day of enrollment was considered as d 1, and the study duration was 10 d. Insulin concentrations and whole-body glucose disappearance were evaluated by an i.v. glucose tolerance test conducted at 12 h and 7 d following the last rbIL-8 injection. Rectal temperature and blood samples were collected on d 1, 2, 3, and 4 at −30 (before treatment, 0830 h), 30, 60, 120, 240, and 360 min relative to treatment, and daily at 0830 h for the rest of the study period. Serum was harvested, and the following parameters were measured: β-hydroxybutyrate (BHB), nonesterified fatty acids, glucose, insulin, plasma urea nitrogen, haptoglobin, and differential blood count. Significant differences were considered when P ≤ 0.05 and a trend if 0.05